Company gets OK from New Zealand for stem-cell therapy

This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Osiris Therapeutics, Inc. has received approval for its stem-cell therapy drug in New Zealand, the second country to approve the drug for treatment of a rare disease.

View the original article here: Osiris gets OK from New Zealand for stem-cell therapy – The Business Journal

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend